Advertisement

Melanoma pp 63-81 | Cite as

Key Signaling Pathways in Normal and Neoplastic Melanocytes

  • Andrew E. AplinEmail author
  • Ashani T. Weeraratna
Reference work entry

Abstract

Signal transduction pathways regulate the proliferation, differentiation, migration, and survival of melanocytes. These signaling pathways are dysregulated during the transformation of melanocytes, often due to somatic mutation of genes within the pathway. One major signaling pathway that highlights this paradigm is the mitogen-activated protein (MAP) kinase pathway. Growth factor signaling via the MAP kinase pathway is required for melanocyte proliferation and survival. MAP kinase signaling is activated in the majority of melanomas through somatic mutations in NRAS, BRAF, and MEK1/2. Regulation of proliferation and survival is also controlled by phosphatidyl-inositol 3′-kinase (PI3K) signaling. PI3K is a major regulator of melanocyte biology and is commonly activated through the mutation/loss of expression of negative not pathway regulators such as PTEN. Alterations in cyclin-dependent kinase signaling are also frequent in melanoma and promote aberrant cell cycle progression. Other pathways such as Gαq, Wnt (canonical and noncanonical), Hippo, Notch, and signaling downstream of Rho family GTPases also play important roles in the aforementioned biological processes, and in some cases are altered in selective subsets of melanoma. The high mutation burden within genes in signaling pathways, the important role of these pathways in melanocytic neoplasms, and the knowledge that melanomas adapt their signaling mechanisms in response to targeted inhibitors make it essential to have a thorough understanding of the key signaling pathways in melanocytes and melanomas.

Keywords

RAS BRAF ERK1/2 PI3K PTEN AKT GNAQ GNA11 Rac Rho PREX CDK4/6 Wnt β-catenin YAP TAZ Notch 

Notes

Acknowledgments

The Aplin Laboratory is supported by the NIH under award numbers: CA196278, CA160495 and CA182635, and by the Melanoma Research Alliance. The Weeraratna Laboratory is supported by NIH grants: CA174746, CA114046, CA207935, CA174523 and grants from the Melanoma Research Foundation and the Melanoma Research Alliance/L’Oreal.

References

  1. Ackermann J et al (2005) Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 65(10):4005–4011PubMedCrossRefPubMedCentralGoogle Scholar
  2. Anastas JN et al (2014) WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest 124(7):2877–2890PubMedPubMedCentralCrossRefGoogle Scholar
  3. Arozarena I et al (2011a) Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19(1):45–57CrossRefGoogle Scholar
  4. Arozarena I et al (2011b) In melanoma, beta-catenin is a suppressor of invasion. Oncogene 30(45):4531–4543PubMedPubMedCentralCrossRefGoogle Scholar
  5. Bachmann IM et al (2005) Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res 11(24 Pt 1):8606–8614PubMedCrossRefPubMedCentralGoogle Scholar
  6. Baenke F et al (2016) Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol 10(1):73–84PubMedCrossRefPubMedCentralGoogle Scholar
  7. Balmanno K, Cook SJ (2009) Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16(3):368–377PubMedCrossRefPubMedCentralGoogle Scholar
  8. Bedogni B (2014) Notch signaling in melanoma: interacting pathways and stromal influences that enhance Notch targeting. Pigment Cell Melanoma Res 27(2):162–168PubMedCrossRefPubMedCentralGoogle Scholar
  9. Bedogni B et al (2008) Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 118(11):3660–3670PubMedPubMedCentralCrossRefGoogle Scholar
  10. Berger MF et al (2012) Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485(7399):502–506PubMedPubMedCentralCrossRefGoogle Scholar
  11. Bhatt KV et al (2005) Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 12(24):3459–3471CrossRefGoogle Scholar
  12. Bhatt KV et al (2007) Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27(Kip1) in human melanoma cells. Oncogene 26(7):1056–1066PubMedCrossRefGoogle Scholar
  13. Biechele TL et al (2012) Wnt/beta-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal 5(206):ra3PubMedPubMedCentralGoogle Scholar
  14. Bigas A, Guiu J, Gama-Norton L (2013) Notch and Wnt signaling in the emergence of hematopoietic stem cells. Blood Cells Mol Dis 51(4):264–270PubMedCrossRefPubMedCentralGoogle Scholar
  15. Boisvert-Adamo K, Aplin AE (2008) Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27(23):3301–3312PubMedCrossRefPubMedCentralGoogle Scholar
  16. Borggrefe T et al (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFbeta/BMP and hypoxia pathways. Biochim Biophys Acta 1863(2):303–313PubMedCrossRefPubMedCentralGoogle Scholar
  17. Botton T et al (2013) Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res 26(6):845–851PubMedCrossRefPubMedCentralGoogle Scholar
  18. Brady SC et al (2009) Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Cancer Res 69(17):6773–6781PubMedPubMedCentralCrossRefGoogle Scholar
  19. Brummer T et al (2003) Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 22(55):8823–8834PubMedCrossRefPubMedCentralGoogle Scholar
  20. Busca R et al (2000) Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J 19(12):2900–2910PubMedPubMedCentralCrossRefGoogle Scholar
  21. Cartlidge RA et al (2008) Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res 21(5):534–544PubMedCrossRefGoogle Scholar
  22. Carvajal RD et al (2014) Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 311(23):2397–2405PubMedPubMedCentralCrossRefGoogle Scholar
  23. Chen X et al (2014) Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene 33(39):4724–4734PubMedCrossRefGoogle Scholar
  24. Chen X et al (2017) RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell 31(5):685–696 e6PubMedPubMedCentralCrossRefGoogle Scholar
  25. Chien AJ et al (2009) Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A 106(4):1193–1198PubMedPubMedCentralCrossRefGoogle Scholar
  26. Chien AJ et al (2014) Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/beta-catenin signaling. PLoS One 9(4):e94748PubMedPubMedCentralCrossRefGoogle Scholar
  27. Chin L et al (1997) Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11(21):2822–2834PubMedPubMedCentralCrossRefGoogle Scholar
  28. Conde-Perez A et al (2015) A caveolin-dependent and PI3K/AKT-independent role of PTEN in beta-catenin transcriptional activity. Nat Commun 6:8093PubMedPubMedCentralCrossRefGoogle Scholar
  29. Curtin JA et al (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353(20):2135–2147PubMedCrossRefGoogle Scholar
  30. Damsky WE et al (2011) β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 20(6):741–754PubMedPubMedCentralCrossRefGoogle Scholar
  31. Dankort D et al (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544–552PubMedPubMedCentralCrossRefGoogle Scholar
  32. Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954PubMedCrossRefPubMedCentralGoogle Scholar
  33. Davies MA et al (2008) A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99(8):1265–1268PubMedPubMedCentralCrossRefGoogle Scholar
  34. Delmas V et al (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 21(22):2923–2935PubMedPubMedCentralCrossRefGoogle Scholar
  35. Deuker MM et al (2015) PI3′-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov 5(2):143–153PubMedCrossRefGoogle Scholar
  36. Dissanayake SK et al (2008) Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res 68(24):10205–10214PubMedPubMedCentralCrossRefGoogle Scholar
  37. Dumaz N et al (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66(19):9483–9491PubMedCrossRefGoogle Scholar
  38. Eskandarpour M et al (2005) Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 115(1):65–73PubMedCrossRefPubMedCentralGoogle Scholar
  39. Feng X et al (2014) Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25(6):831–845PubMedPubMedCentralCrossRefGoogle Scholar
  40. Ferguson B et al (2015) Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression. Oncogene 34(22):2879–2886PubMedCrossRefPubMedCentralGoogle Scholar
  41. Gewinner C et al (2009) Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16(2):115–125PubMedPubMedCentralCrossRefGoogle Scholar
  42. Gray-Schopfer VC et al (2006) Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 95(4):496–505PubMedPubMedCentralCrossRefGoogle Scholar
  43. Ha L et al (2007) ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A 104(26):10968–10973PubMedPubMedCentralCrossRefGoogle Scholar
  44. Harbour JW et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413PubMedPubMedCentralCrossRefGoogle Scholar
  45. Hoek KS et al (2006) Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19(4):290–302PubMedCrossRefPubMedCentralGoogle Scholar
  46. Horrigan SK et al (2017) Replication study: melanoma genome sequencing reveals frequent PREX2 mutations. Elife 6:e21634PubMedPubMedCentralCrossRefGoogle Scholar
  47. Huang JL, Urtatiz O, Van Raamsdonk CD (2015) Oncogenic G protein GNAQ induces uveal melanoma and intravasation in mice. Cancer Res 75(16):3384–3397PubMedCrossRefPubMedCentralGoogle Scholar
  48. Hutchinson KE et al (2013) BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 19(24):6696–6702PubMedCrossRefPubMedCentralGoogle Scholar
  49. Inoue-Narita T et al (2008) Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res 68(14):5760–5768PubMedCrossRefGoogle Scholar
  50. Jakob JA et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014–4023PubMedCrossRefPubMedCentralGoogle Scholar
  51. Joseph EW et al (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 107(33):14903–14908PubMedPubMedCentralCrossRefGoogle Scholar
  52. Kannan K et al (2003) Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci U S A 100(3):1221–1225PubMedPubMedCentralCrossRefGoogle Scholar
  53. Kaur A et al (2016) sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 532:250PubMedPubMedCentralCrossRefGoogle Scholar
  54. Klein RM et al (2008) B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell 19(2):498–508PubMedPubMedCentralCrossRefGoogle Scholar
  55. Koelsche C et al (2015) Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. Brain Pathol 25(2):202–208PubMedCrossRefPubMedCentralGoogle Scholar
  56. Krauthammer M et al (2015) Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 47(9):996–1002PubMedPubMedCentralCrossRefGoogle Scholar
  57. Kwong LN et al (2012) Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18:1503PubMedPubMedCentralCrossRefGoogle Scholar
  58. Lamar JM et al (2012) The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 109(37):E2441–E2450PubMedPubMedCentralCrossRefGoogle Scholar
  59. Larribere L et al (2004) PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 11(10):1084–1091PubMedCrossRefPubMedCentralGoogle Scholar
  60. Larue L et al (2009) Bypassing melanocyte senescence by beta-catenin: a novel way to promote melanoma. Pathol Biol (Paris) 57:543CrossRefGoogle Scholar
  61. Lee EK et al (2013) The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol Cell Biol 33(22):4422–4433PubMedPubMedCentralCrossRefGoogle Scholar
  62. Li Chew C et al (2015) In vivo role of INPP4B in tumor and metastasis suppression through regulation of PI3K-AKT signaling at endosomes. Cancer Discov 5(7):740–751PubMedCrossRefPubMedCentralGoogle Scholar
  63. Li A et al (2012) Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism. J Invest Dermatol 132(11):2610–2621PubMedPubMedCentralCrossRefGoogle Scholar
  64. Lindsay CR et al (2011) P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun 2:555PubMedPubMedCentralCrossRefGoogle Scholar
  65. Lindsay CR et al (2015) A Rac1-independent role for P-Rex1 in melanoblasts. J Invest Dermatol 135(1):314–318PubMedCrossRefPubMedCentralGoogle Scholar
  66. Lito P et al (2012) Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22(5):668–682PubMedPubMedCentralCrossRefGoogle Scholar
  67. Liu H et al (2015) Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling. Oncol Rep 34(1):295–301PubMedCrossRefPubMedCentralGoogle Scholar
  68. Madhunapantula SV, Sharma A, Robertson GP (2007) PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res 67(8):3626–3636PubMedCrossRefPubMedCentralGoogle Scholar
  69. Marsh Durban V et al (2013) Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest 123(12):5104–5118PubMedPubMedCentralCrossRefGoogle Scholar
  70. McKay MM, Freeman AK, Morrison DK (2011) Complexity in KSR function revealed by Raf inhibitor and KSR structure studies. Small GTPases 2(5):276–281PubMedPubMedCentralCrossRefGoogle Scholar
  71. Mense SM et al (2015) PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion. Sci Signal 8(370):ra32PubMedPubMedCentralCrossRefGoogle Scholar
  72. Michaloglou C et al (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436(7051):720–724PubMedCrossRefPubMedCentralGoogle Scholar
  73. Monahan KB et al (2010) Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 29(43):5809–5817PubMedPubMedCentralCrossRefGoogle Scholar
  74. Nallet-Staub F et al (2014) Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma. J Invest Dermatol 134(1):123–132PubMedCrossRefPubMedCentralGoogle Scholar
  75. Nemeth MJ et al (2007) Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. Proc Natl Acad Sci U S A 104(39):15436–15441PubMedPubMedCentralCrossRefGoogle Scholar
  76. Nikolaev SI et al (2012) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44(2):133–139CrossRefGoogle Scholar
  77. O’Connell MP, Weeraratna AT (2009) Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt. Pigment Cell Melanoma Res 22:724PubMedPubMedCentralCrossRefGoogle Scholar
  78. O’Connell MP et al (2013) Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 3(12):1378–1393PubMedPubMedCentralCrossRefGoogle Scholar
  79. Paraiso KHT et al (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71(7):2750–2760PubMedPubMedCentralCrossRefGoogle Scholar
  80. Pollock PM et al (2003) High frequency of BRAF mutations in nevi. Nat Genet 33(1):19–20PubMedCrossRefPubMedCentralGoogle Scholar
  81. Pratilas CA et al (2009) V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 106(11):4519–4524PubMedPubMedCentralCrossRefGoogle Scholar
  82. Ranganathan P, Weaver KL, Capobianco AJ (2011) Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 11(5):338–351PubMedCrossRefPubMedCentralGoogle Scholar
  83. Robbins PF et al (1996) A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183(3):1185–1192PubMedCrossRefPubMedCentralGoogle Scholar
  84. Rushworth LK et al (2006) Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 26(6):2262–2272PubMedPubMedCentralCrossRefGoogle Scholar
  85. Sanchez IM, Aplin AE (2014) Hippo: hungry, hungry for melanoma invasion. J Invest Dermatol 134(1):14–16PubMedPubMedCentralCrossRefGoogle Scholar
  86. Sauter ER et al (2002) Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62(11):3200–3206PubMedPubMedCentralGoogle Scholar
  87. Scortegagna M et al (2014) Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf::Pten melanoma. Oncogene 33:4330–4339PubMedCrossRefPubMedCentralGoogle Scholar
  88. Scortegagna M et al (2015) PDK1 and SGK3 contribute to the growth of BRAF-mutant melanomas and are potential therapeutic targets. Cancer Res 75(7):1399–1412PubMedPubMedCentralCrossRefGoogle Scholar
  89. Scott G, Cassidy L, Busacco A (1997) Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. J Invest Dermatol 108(2):147–153PubMedCrossRefPubMedCentralGoogle Scholar
  90. Shain AH et al (2015) Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet 47(10):1194–1199PubMedPubMedCentralCrossRefGoogle Scholar
  91. Shao Y, Aplin AE (2012) ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis 3:e253PubMedPubMedCentralCrossRefGoogle Scholar
  92. Shao H et al (2011) Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene 30(42):4316–4326PubMedCrossRefGoogle Scholar
  93. Shin MK et al (1999) The temporal requirement for endothelin receptor-B signalling during neural crest development. Nature 402(6761):496–501PubMedCrossRefGoogle Scholar
  94. Solit DB et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439(7074):358–362CrossRefGoogle Scholar
  95. Sotillo R et al (2001) Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci U S A 98(23):13312–13317PubMedPubMedCentralCrossRefGoogle Scholar
  96. Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523(7559):231–235PubMedCrossRefGoogle Scholar
  97. Stahl JM et al (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 64(19):7002–7010PubMedCrossRefGoogle Scholar
  98. TCGA (2015) Genomic classification of cutaneous melanoma. Cell 161(7):1681–1696CrossRefGoogle Scholar
  99. Van Brocklin MW et al (2009) Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res 69(5):1985–1994CrossRefGoogle Scholar
  100. Van Raamsdonk CD et al (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229):599–602PubMedCrossRefGoogle Scholar
  101. Van Raamsdonk CD et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191–2199PubMedPubMedCentralCrossRefGoogle Scholar
  102. Wan PT et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6):855–867PubMedCrossRefGoogle Scholar
  103. Watson IR et al (2014) The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res 74(17):4845–4852PubMedPubMedCentralCrossRefGoogle Scholar
  104. Weber CK et al (2001) Active ras induces heterodimerization of cRaf and BRaf. Cancer Res 61(9):3595–3598PubMedGoogle Scholar
  105. Webster MR, Kugel CH 3rd, Weeraratna AT (2015a) The Wnts of change: how Wnts regulate phenotype switching in melanoma. Biochim Biophys Acta 1856(2):244–251PubMedPubMedCentralGoogle Scholar
  106. Webster MR et al (2015b) Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell Melanoma Res 28(2):184–195PubMedCrossRefGoogle Scholar
  107. Weeraratna AT et al (2002) Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1(3):279–288PubMedCrossRefGoogle Scholar
  108. Weiss MB et al (2012) TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res 72(24):6382–6392PubMedPubMedCentralCrossRefGoogle Scholar
  109. Welch HC (2015) Regulation and function of P-Rex family Rac-GEFs. Small GTPases 6(2):49–70PubMedPubMedCentralCrossRefGoogle Scholar
  110. Wolfel T et al (1995) A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269(5228):1281–1284PubMedCrossRefPubMedCentralGoogle Scholar
  111. Xing F et al (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31(4):446–457PubMedCrossRefPubMedCentralGoogle Scholar
  112. Yeh I et al (2017) Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating nevi. Nat Com 8(1):644.  https://doi.org/10.1038/s41467-017-00758-3CrossRefGoogle Scholar
  113. Zhang G et al (2016) Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest 126(5):1834–1856PubMedPubMedCentralCrossRefGoogle Scholar
  114. Zheng B et al (2009) Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33(2):237–247PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Cancer Biology and Sidney Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Melanoma Research Center, Immunology, Microenvironment and MetastasisThe Wistar InstitutePhiladelphiaUSA

Section editors and affiliations

  • David E. Fisher
    • 1
  • Nick Hayward
    • 2
  • David C. Whiteman
    • 3
  • Keith T. Flaherty
    • 4
  • F. Stephen Hodi
    • 5
    • 6
  • Hensin Tsao
    • 7
    • 8
  • Glenn Merlino
    • 9
  1. 1.Department of Dermatology, Harvard/MGH Cutaneous Biology Research Center, and Melanoma Program, MGH Cancer CenterMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  2. 2.QIMR Berghofer Medical Research InstituteHerstonAustralia
  3. 3.QIMR Berghofer Medical Research InstituteHerstonAustralia
  4. 4.Henri and Belinda Termeer Center for Targeted TherapiesMGH Cancer CenterBostonUSA
  5. 5.FraminghamUSA
  6. 6.Department of Medicine, Brigham and Women's HospitalDana-Farber Cancer InstituteBostonUSA
  7. 7.AuburndaleUSA
  8. 8.Harvard-MIT Health Sciences and TechnologyCambridgeUSA
  9. 9.Center for Cancer ResearchNational Cancer InstituteBethesdaUSA

Personalised recommendations